Steven Gillis, Ph.D., Managing Director of ARCH Venture Partners, Named Chairman of the Board; Michael Steinmetz, Ph.D., of Clarus Ventures to Join Board ANN ARBOR, Mich. – February 15, 2012 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Steven Gillis, Ph.D., managing… Read More

ANN ARBOR, Mich. – January 31, 2012 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company will present at the following industry conferences. World Cancer Metabolism Summit, being held Feb. 1-2 at the Washington Marriott Hotel in Washington, D.C. Gary D.… Read More

Partnership Focused on Developing Drugs Targeting the Th17 Pathway through the Inhibition of RORγt to Treat Autoimmune Diseases ANN ARBOR, Mich. – December 21, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research… Read More

ANN ARBOR, Mich. – October 4, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that Kathleen M. Metters, Ph.D., former senior vice president and head of worldwide basic research at Merck, has been named president and chief executive officer and a member… Read More

PLYMOUTH, Mich. – September 7, 2011 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company will present at the following industry conferences this fall: BioPharm America™ 2011, being held Sept. 7-9 at the Westin Boston Waterfront in Boston. Gary D. Glick,… Read More

PLYMOUTH, Mich. – March 27, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that the company presented at the following industry conferences: Society for Biomolecular Sciences (SBS) 17th Annual Conference and Exhibition, held March 27-31 in Orlando, Fla. Xiao Hu, Ph.D., senior… Read More

Companies to Focus on Developing Drugs that Inhibit RORγt PLYMOUTH, Mich. – March 3, 2011 – Lycera Corporation, a biopharmaceutical company pioneering innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target… Read More